Daily Roundup

CMP.ASX NEU.ASX NGI.ASX ARU.ASX CYB.ASX

Here is a news roundup covering the top announcements for the day:

Compumedics Reports Record Sales Orders in H1 FY25
Compumedics Ltd, a global medical device company, has announced record sales orders of $32.8m for the first half of the 2025 financial year. This represents a 55% increase compared to the same period last year, driven by exceptional growth in the company's USA business. The USA sleep and Neuroscan brain analysis business were the key drivers, with sales orders up 208%. Compumedics also saw robust sales order growth in Asia and Europe. The company is well-positioned to accelerate growth in the second half as new sales resources come on board in the USA.

Neuren Submits Trofinetide Marketing Application in Europe
Neuren Pharmaceuticals has announced that its partner Acadia Pharmaceuticals has submitted a Marketing Authorization Application to the European Medicines Agency for trofinetide, a potential treatment for Rett syndrome. If granted, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union. Acadia anticipates potential approval in Q1 2026 and plans to initiate Managed Access Programs in Europe in Q2 2025.

Navigator Global Investments Reports Solid AUM Growth
Navigator Global Investments Ltd has reported its December 2024 quarter AUM update, with total firm-level AUM of USD 79 billion and total ownership-adjusted AUM of USD 27 billion. This represents a 3.9% year-on-year growth in total ownership-adjusted AUM. The company's Lighthouse, NGI Strategic Portfolio, and NGI Strategic Private Markets businesses all saw solid AUM growth during the period.

Arafura Secures A$200M Investment from NRFC
Arafura Rare Earths Ltd has signed a binding term sheet with the National Reconstruction Fund Corporation (NRFC) for a A$200 million investment commitment to support the development of the Nolans Project. The investment will be made through convertible notes, with a conversion period of seven years. This is expected to be a catalyst for additional equity funding and attract further strategic investment to deliver Australia's first ore-to-oxide rare earths processing operation.

AUCyber Provides Trading Update, Rejects Takeover Bid
AUCyber Limited reported an Underlying EBITDA loss of $1.6 million on revenues of $12.2 million for the 6 months ended 31 December 2024, which is below expectations. The company's board has terminated the CEO and is evaluating cost optimization and growth initiatives. AUCyber also received an unsolicited takeover bid from 5GN Networks, but the board recommends shareholders reject it.